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Supplementary Materials and Methods
Pilot study of cyclophosphamide treatment
Cyclophosphamide (CTX) treatment started when tumors in 4T1 tumor-bearing mice reached a tumor volume of 100-150 mm 3 . Mice were intraperitoneally administered CTX (75 mg/kg, on days 0, 3, 6, and 9). On days 0, 8, and 16, CD206-targeted NIRF imaging (n = 5 per group) and flow cytometry analysis of CD206 and F4/80 (n = 5 per group) were performed using the protocols described in the main text.
Characterization of CD206-targeting probes
The purity of Dye-αCD206 was determined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) followed by near-infrared fluorescence (NIRF) imaging using a Maestro In-Vivo Imaging System (CRI, Woburn, MA). The purity of 125 I-αCD206 was determined by the instant thin-layer chromatography (ITLC) using 85% methanol as the mobile phage.
In vitro targeting specificity of 125 I-αCD206 CD206 + RAW264.7 cells grown in 24-well plates were incubated with 0.1 µCi 125 I-αCD206 (with or without a blocking dose of unlabeled αCD206) or 125 I-IgG (isotypematched control) for 2 h at 4°C. After washing with pre-chilled PBS, cells were collected by trypsinization using a 0.25% trypsin solution, and cell-associated radioactivity was measured using a γ-counter (Packard, Meriden, CT). Results are expressed as the percentage of the total added dose per 10 5 cells (%AD/10 5 cells).
Zoledronic acid and CTX combination treatment
3 4T1 tumor-bearing mice were separated into 4 groups (n = 8 per group) and treated with (1) PBS, (2) zoledronic acid (ZA, 150 μg/kg daily in PBS, from day 0 to day 13), (3) a single dose of CTX (150 mg/kg in PBS, once on day 0) or (4) ZA plus CTX.
Tumor size was monitored every other day. On day 8, 5 mice from each group were i.v. administered 0.5 nmol Dye-αCD206, and NIRF imaging was performed at 24 h p.i.;
mice were NIRF-imaged using a Meastro In-Vivo Imaging System (CRI, Woburn, MA).
NIRF imaging in a dual inflammation and 4T1 tumor-bearing mouse model
For the dual inflammation and 4T1 tumor-bearing mouse model, 50 μL of turpentine was injected in the left thigh muscle of the 4T1 tumor-bearing BALB/c mice at 24 h before the NIRF imaging experiments. For NIRF imaging, mice were intravenously administered 0.5 nmol of Dye-αCD206 or Dye-IgG (n = 5 per group).
NIRF imaging was performed at 24 h postinjection using a Maestro In-vivo Imaging System (CRI, Woburn, MA).
For ex vivo validation of CD206 and F4/80 expression, 3 mice bearing inflammation and 4T1 tumors were euthanized. The tumors, inflamed tissues, and muscles were harvested and frozen cut into 8-μm thick sections. The sections were stained for F4/80
and CD206 using the protocol described in the maintext. Inset, ZA and CTX treatment schedule. *, P <0.05; **, P <0.01; ***, P <0.001. 
